Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits

CMAJ. Canadian Medical Association Journal

Volumn 154, Issue 12, 1996, Pages 1837-1843

  Marshall, Kenneth G ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMMUNITY; PREVENTIVE MEDICINE; PUBLISHING; REVIEW; RISK BENEFIT ANALYSIS; SCREENING; TREATMENT OUTCOME;

EID: 0029979877     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Kassirer JP: Adding insult to injury: usurping patients' prerogatives. N Engl J Med 1983; 308: 898-901
2. Angell M: Patients' preferences in randomized clinical trials. N Engl J Med 1984; 310: 1385-1387
3. Kassirer JP: Incorporating patients' preferences into medical decisions. N Engl J Med 1994; 330: 1895-1896
4. O'Meara JJ III, McNutt RA, Evans AT et al: A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994; 330: 1864-1869
5. Nease RF Jr, Kneeland T, O'Connor GT et al: Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines JAMA 1995; 273: 1185-1190
6. Hlatky MA: Patient preferences and clinical guidelines. [editorial] JAMA 1995; 273: 1219-1220
7. Skrabanek P, McCormick J: Follies and Fallacies in Medicine, Prometheus Books, Buffalo, NY, 1990: 32-33
8. Catalona WJ, Smith DS, Ratliff TL et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-954
9. Smith DS, Catalona WJ: The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152: 1732-1736
10. Handley MR, Stuart ME: The use of prostate specific antigen for prostate cancer screening: a managed care perspective. J Urol 1994; 152: 1689-1692
11. Black WC, Welch HG: Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993; 328: 1237-1248
12. Chodak GW, Thisted RA, Gerber GS et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-248
13. Jones GW: Prospective, conservative management of localized prostate cancer. Cancer 1992; 70 (suppl): 307-310
14. Whitmore WF Jr, Warner JA, Thompson IM Jr: Expectant management of localized prostatic cancer. Cancer 1991; 67: 1091-1096
15. Adolfsson J, Carstensen J, Lowhagen T: Deferred treatment in clinically localized prostatic carcinoma. Br J Urol 1992; 69: 183-187
16. Johansson JE, Adami HO, Andersson SO et al: Natural history of localized prostatic cancer: a population-based study in 223 untreated patients. Lancet 1989; 1: 799-803
17. Johansson JE, Adami HO, Andersson SO et al: High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 2191-2196
18. Moskovitz B, Nitecki A, Richter Levin D: Cancer of the prostate: Is there a need for aggressive treatment? Urol Int 1987; 42: 49-52
19. Goodman CM, Busuttil A, Chisholm GD: Age, and size and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate. Br J Urol 1988; 62: 576-580
20. Johansson J-E: Expectant management of early stage prostatic cancer: Swedish experience. J Urol 1994; 152: 1753-1756
21. Chodak GW: The role of watchful waiting in the management of localized prostate cancer. J Urol 1994; 152: 1766-1768
22. Smith GD, Song F, Sheldon TA: Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993; 306: 1367-1373 [Erratum, BMJ 1993; 306: 1648]
23. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-1389
24. Shepherd J, Cobbe SM, Ford I et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307
25. Canadian Task Force on the Periodic Health Examination: Canadian Guide to Clinical Preventive Health Care, Health Canada, Ottawa, 1994: 655
26. Nyström L, Rutqvist LE, Wall S et al: Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993; 341: 973-978
27. Ettinger B, Grady D: The waning effect of postmenopausal estrogen therapy on osteoporosis. N Engl J Med 1993; 329: 1192-1193
28. Cauley JA, Seeley DG, Ensrud K et al for the Study of Osteoporotic Fractures Research Group: Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122: 9-16
29. Stampfer MJ, Colditz GA, Willett WC et al: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756-762
30. Coronary heart disease attributable to sedentary lifestyle - selected states, 1988. MMWR 1990; 39: 542-545
31. Powell KE, Thompson PD, Caspersen CJ et al: Physical activity and the incidence of coronary heart disease. Annu Rev Public Health 1987; 8: 253-287
32. Morris JN, Clayton DG, Everitt MG et al: Exercise in leisure time: coronary attack rate and death rates. Br Heart J 1990; 63: 325-334
33. Paffenbarger RS Jr, Hyde RT, Wing AL et al: The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328: 538-545
34. Shaper AG, Wannamethee G: Physical activity and ischaemic heart disease in middle-aged British men. Br Heart J 1991; 66: 384-394
35. Lakka TA, Venalainen JM, Rauremaa R et al: Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men. N Engl J Med 1994; 330: 1549-1554
36. Who's for tennis? [editorial] Lancet 1990; 336: 1157-1158
37. Nelson ME, Fiatarone MA, Morganti CM et al: Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial. JAMA 1994; 272: 1909-1914
38. Perez CR, Galan Galan F, Dilsen G: Risk factors for hip fracture in Spanish and Turkish women. Bone 1993; 14 (suppl 1): S69-S72
39. Jaglal SB, Kreiger N, Darlington G: Past and recent physical activity and risk of hip fracture. Am J Epidemiol 1993; 138: 107-118
40. Paganini-Hill A, Chao A, Ross RK et al: Exercise and other factors in the prevention of hip fracture: the Leisure World study. Epidemiology 1991; 2: 16-25
41. Henderson BE, Paganini-Hill A, Ross RK: Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988; 159: 312-317
42. Canadian Menopause Consensus Conference. J Soc Obstet Gynaecol Can 1994; 16: 1647-1697
43. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
44. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309
45. Lasker RD: The diabetes control and complications trial. [editorial] N Engl J Med 1993; 329: 1035-1036
46. American Diabetes Association: Position statement: implications of the diabetes control and complications trial. Diabetes 1993; 42: 1555-1558
47. Curb JD, Borhani NO, Blaszkowski TP et al. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA 1985; 253: 3263-3268
48. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104
49. Engelland AL, Alderman MH, Powell HB: Blood pressure control in private practice: a case report. Am J Public Health 1979; 69: 25-29
50. Gillum RF, Neutra RR, Stason WB et al: Determinants of dropout rate among hypertensive patients in an urban clinic. J Community Health 1979; 5: 94-100
51. Andrade SE, Walker AM, Gottlieb LK et al: Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-1131
52. Peto R, Collins R, Gray R: Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 1995; 48: 23-40
53. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. Ann NY Acad Sci 1993; 703: 314-340
54. Collins R, Peto R, Flather M et al. ISIS-4 - a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685
55. Easterbrooke PJ, Berlin JA, Gopalan R et al: Publication bias in clinical research. Lancet 1991; 337: 867-872
56. Berlin JA: Will publication bias vanish in the age of online journals? [editorial] Online J Curr Clin Trials 1992; Jul 8 (doc 12) [1337 words]
57. Dickersin K, Min YI: NIH clinical trials and publications bias. [article] Online J Curr Trials 1993; Apr 28 (doc 50) [4967 words]
58. Moher D: Clinical-trial registration: a call for its implementation in Canada. [editorial] Can Med Assoc J 1993; 149: 1657-1658
59. Robinson A: Research, practice and the Cochrane Collaboration. Can Med Assoc J 1995; 152: 883-889
60. Ravnskov U: Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ 1992; 305: 15-19
61. Guyatt C, Jaeschke R, Heddle N et al: Basic statistics for clinicians: I. Hypothesis testing. Can Med Assoc J 1995; 152: 27-32